Show simple item record

dc.contributor.authorNigo, Masayuki
dc.contributor.authorMunita, Jose M
dc.contributor.authorArias, Cesar A
dc.contributor.authorMurray, Barbara E
dc.date.accessioned2020-07-17T17:24:40Z
dc.date.available2020-07-17T17:24:40Z
dc.identifier.issn1534-3146spa
dc.identifier.urihttp://hdl.handle.net/20.500.12495/3552
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherSpringer Linkspa
dc.relation.ispartofseriesCurrent Infectious Disease Reports, 1534-3146, Vol. 16, No. 10, 2014 p. 1-10spa
dc.relation.urihttps://link.springer.com/article/10.1007/s11908-014-0431-zspa
dc.titleWhat’s new in the treatment of enterococcal endocarditis?spa
dc.type.localArtículo de revista
dc.subject.keywordsEndocarditisspa
dc.subject.keywordsEnterococcalspa
dc.subject.keywordsEnterococcispa
dc.subject.keywordsVREspa
dc.subject.keywordsEnterococcusspa
dc.identifier.doihttps://doi.org/10.1007/s11908-014-0431-zspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.publisher.journalCurrent Infectious Disease Reportsspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.identifier.instnameinstname:Universidad El Bosque
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourlhttps://repositorio.unbosque.edu.co
dc.title.translatedWhat’s new in the treatment of enterococcal endocarditis?spa
dc.description.abstractenglishEnterococcus spp. are among the common pathogens causing infective endocarditis (IE). Despite major medical advances and new potent antimicrobial agents, the mortality has not significantly improved for several decades. The usual lack of bactericidal activity of penicillin or ampicillin, the toxicity from the combination of penicillin plus aminoglycosides, and the increased reports of high-level resistance to aminoglycosides have led to the exploration of other regimens for treatment of Enterococcus faecalis IE. As an example, ampicillin plus ceftriaxone is now a well-recognized regimen for this organism. However, the emerging of new drug resistances in Enterococcus faecium dramatically reduces the therapeutic alternatives for this organism in IE which continues to be an immense challenge for clinicians even with the availability of newer antimicrobial agents. This article summarizes the current treatment options for enterococcal endocarditis and reviews of recent publications on the topic.spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abiertospa
dc.date.issued2014-10


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record